EP08.03-002 Local Ablative Therapy in Oligoprogressive NSCLC - Results from a Tertiary Cancer Center of India

Abstract

Approximately half of the NSCLC patients on targeted therapy or after curative treatment of localized disease experience oligoprogression (OP). Local ablative therapy (LAT) of OP sites can eradicate the resistant clones at and restore the overall sensitivity of systemic therapy. LAT can either delay the initiation of systemic therapy or allow to continue usage of same systemic therapy especially tyrosine kinase inhibitors (TKI) and immunotherapy. In this retrospective study, we evaluated the outcomes of LAT for NSCLC patients with OP disease.